Bipolar Disorder Clinical Trial
Verified date | May 2012 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Observational |
ADHD in the adult population is associated with several measures of harmful dysfunction. For
example, adult ADHD is associated with high rates of separation/divorce and never-married
status, lower educational attainment and occupational achievement, absenteeism,
presenteeism, and job termination, as well as decreased social function. Individuals with
adult ADHD are more likely than controls to have a comorbid diagnosis of bipolar disorder,
alcohol and substance abuse, as well as antisocial personality disorder.
Psychostimulants are the most frequently employed medications in the treatment of adult
ADHD. Several psychostimulants are Health Canada and US FDA-approved for the treatment of
ADHD symptoms in adulthood.
Hitherto, no trial has evaluated the safety and efficacy of a psychostimulant in the
treatment of ADHD symptomatology in adult individuals with bipolar disorder.
Vyvanse is the first prodrug stimulant indicated for the treatment of adult (and pediatric)
ADHD. Vyvanse is a therapeutically inactive molecule (i.e. prodrug). After oral ingestion,
lisdexamfetamine is converted to l-lysine, a naturally occurring essential amino acid, and
active d-amphetamine, which is responsible for the drug's activity. Vyvanse provides a
longer duration of effect consistent throughout the day with reduced potential for risk of
abuse. Vyvanse is generally well tolerated with an adverse event profile similar to other
psychostimulant medications. Available evidence indicates that in most treated subjects,
Vyvanse is weight-neutral and/or is associated with weight loss. Moreover, in some
individuals, it is associated with improvement in both glucose and lipid homeostasis.
The evaluation of safety/tolerability profiles as well as the effectiveness of
lisdexamfetamine in a "real-world" population has significant translational value.
Status | Completed |
Enrollment | 45 |
Est. completion date | January 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Outpatient status - Male or female subjects between the ages of 18 to 55 years, inclusive - Primary diagnosis of Bipolar Disorder and ADHD according to criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) using the Mini International Neuropsychiatric Interview. - Agree to use reliable method of birth control - YMRS score </= 12 - CGI-BP < 6 - Able and willing to provide a written informed consent Exclusion Criteria: - Current Axis I primary psychiatric diagnosis other than Bipolar Disorder and ADHD - Current Axis II psychiatric disorder of primary clinical focus - Active alcohol as well as illicit or other substance abuse during the past 3 months - Current clinically unstable medical condition. - Inability to understand and engage in the process of informed consent. - Inability to cooperate with study procedures. - Presence of known allergies or hypersensitivity to lisdexamfetamine - History of destabilization when exposed to psychostimulant medication - Current high risk of suicide - Current treatment with corticosteroids - Electroconvulsive therapy in the last 1 year - Current participation in a separate clinical research study involving an investigational drug |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | Mood Disorders Psychopharmacology Unit | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Shire |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Metabolic parameters | Weight; BMI; Waist circumference | Screening (Week -1) to Endpoint (Week 4); Completed weekly on all 6 visits | No |
Secondary | ADHD-RS | Measure of ADHD symptoms | Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits | No |
Secondary | CAARS | Measure of ADHD symptoms | Baseline (Week 0) to Endpoint (Week 4); completed weekly on 5 visits | No |
Secondary | CGI-BP | Baseline (Week 0) to Endpoint (Week 4); Completed weekly on all 6 visits | Yes | |
Secondary | Q-LES-Q | Quality of Life | Baseline (Week 0) and Endpoint (Week 4); Completed on 2 visits | No |
Secondary | AAQoL | Quality of Life | Baseline (Week 0), Week 2, Endpoint (Week 4); Completed on 3 visits | No |
Secondary | Metabolic Peptidergic systems | Insulin; Resistin; Ghrelin; Leptin; Adiponectin | Baseline (Week 0) and Endpoint (Week 4); Completed on 2 visits | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |